Evidence map›Paper›PMID 42312290›Full record

ArticleLiver cancer2026

The 2024 International Liver Transplant Society and International Liver Cancer Association Consensus Recommendations for Liver Transplantation for Liver Cancer.

Sudha Kodali, Laura Kulik, Antonio D'Alessio, Eleonora De Martin, Abdul Rahman Hakeem, Monica Lewinska, Stacie Lindsey, Ken Liu, Zorana Maravic, Madhukar S Patel and 14 more

Abstract read
In one paragraph

Article in Liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Sudha KodaliJC Walter Transplant Center, Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston Methodist Hospital, Houston, TX, USA.
Laura KulikNorthwestern Medicine, Chicago, IL, USA.
Antonio D'AlessioDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Eleonora De MartinAP-HP Hôpital Paul Brousse, Centre Hépato-Biliaire, Inserm UMR-S 1193, Université Paris-Saclay, Villejuif, France.
Abdul Rahman HakeemLeeds Liver Unit, St James' University Hospital, Leeds, UK.
Monica LewinskaBiotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
Stacie LindseyCholangiocarcinoma Foundation, Herriman, UT, USA.
Ken LiuAW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Zorana MaravicDigestive Cancers Europe, Brussels, Belgium.
Madhukar S PatelDepartment of Surgery, Division of Surgical Transplantation, UT Southwestern Medical Center, Dallas, TX, USA.
David J PinatoDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Ashwin RammohanThe Institute of Liver Disease and Transplantation, Dr. Rela Institute and Medical Centre, Bharath Institute of Higher Education and Research, Chennai, India.
Nicole RichDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Marco Sanduzzi ZamparelliBCLC Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
David W VictorJC Walter Transplant Center, Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston Methodist Hospital, Houston, TX, USA.
Carmen VinaxiaHepatology and Liver Transplantation, Digestive Diseases Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Elizabeth W BromboszDepartment of Surgery, Houston Methodist Hospital, Houston, TX, USA.
Augusto VillanuevaMount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Tim MeyerUCL Cancer Institute, University College London, London, UK.
Nazia SelznerDepartment of Medicine, Division of Gastroenterology, University of Toronto, Toronto, ON, Canada.
R Mark GhobrialJC Walter Transplant Center, Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston Methodist Hospital, Houston, TX, USA.
Mohamed RelaThe Institute of Liver Disease and Transplantation, Dr. Rela Institute and Medical Centre, Bharath Institute of Higher Education and Research, Chennai, India.
Gonzalo SapisochinMulti-Organ Transplant Program, University Health Network, Toronto, ON, Canada.
and the ILTSILCAconsensus2024 Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver transplantation (LT) provides the best long-term survival outcomes for patients with liver cancer. As a result, the field of transplant oncology has grown greatly over the past few decades, and many centers have expanded their criteria to allow increased access to LT for liver malignancies. Center-level guidelines and practices in transplant oncology significantly vary across the world, leading to debate regarding the best course of treatment for this patient population. An international consensus conference was convened by the International Liver Transplantation Society and the International Liver Cancer Association on February 1-2, 2024, in Valencia, Spain, to establish a more universal consensus regarding LT for oncologic indications. The conference followed the Delphi process, followed by external expert review. Consensus statements were accepted regarding patient assessment and waitlisting criteria, pretransplant treatment (including immunotherapy) and downstaging, living donor LT, post-LT patient management, and patient- and caregiver-related outcomes. The multidisciplinary participants in the consensus conference provided up-to-date recommendations regarding the selection and management of patients with liver cancer being considered for LT. Although participants deferred to center protocols in many cases, there was great interest in safely expanding access to LT for patients with larger tumor burden and biologically amenable lesions.

Indexed as

Consensus development conferenceHepatocellular carcinomaIntrahepatic cholangiocarcinomaLiver transplantationTransplant oncology

Identifiers

PMID42312290
PMCPMC13271748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.